Active substanceEthyl methylhydroxypyridine succinateEthyl methylhydroxypyridine succinate
Similar drugsTo uncover
  • Astrox
    solution w / m in / in 
    HOMEKSFARM LLC     Russia
  • Medomex®
    pills inwards 
       
  • Mexident®
    solution w / m in / in 
  • Mexidol®
    solution w / m in / in 
    FARMASOFT NPK, LLC     Russia
  • Mexidol®
    pills inwards 
    FARMASOFT NPK, LLC     Russia
  • Mexidol® FORTE 250
    pills inwards 
    FARMASOFT NPK, LLC     Russia
  • Mexicor®
    solution w / m in / in 
    EcoFarmInvest, LLC     Russia
  • Mexicor®
    capsules inwards 
    EcoFarmInvest, LLC     Russia
  • Mieleklek-Lekpharm
    solution w / m in / in 
    LEKFARM, SOOO     Republic of Belarus
  • Mexiprem ®
    solution w / m in / in 
    NIZHFARM, JSC     Russia
  • Mexiprem ®
    pills inwards 
    NIZHFARM, JSC     Russia
  • Mexinin®
    solution w / m in / in 
    BRENDFARMA, LLC     Russia
  • Metostabil
    solution w / m in / in 
    ATOLL, LLC     Russia
  • Metostabil
    pills inwards 
    ATOLL, LLC     Russia
  • MetucinWel
    solution w / m in / in 
    VELFARM, LLC     Republic of San Marino
  • Neurocardia
    solution w / m in / in 
  • Neurox®
    solution w / m in / in 
  • Proinin®
    solution w / m in / in 
  • Cerekard
    solution w / m in / in 
    EKOFARMPLUS, CJSC     Russia
  • Dosage form: & nbspsolution for intravenous and intramuscular administration
    Composition:

    1 ml of the preparation contains:

    active substance: ethylmethylhydroxypyridine succinate - 50 mg;

    auxiliary substance: water for injection - up to a volume of 1 ml.

    Description:Colorless or slightly colored transparent liquid.
    Pharmacotherapeutic group:Antioxidant
    ATX: & nbsp

    N.07.X.X   Other drugs for the treatment of diseases of the nervous system

    Pharmacodynamics:

    Mefifin® belongs to the group of compounds of 3-hydroxypyridine and succinic acid and has antioxidant, antihypoxic, membrane-stabilizing, nootropic, stress-protective, anticonvulsant and anxiolytic effects.

    Mefifin® acts as a free radical inhibitor, inhibits the processes of lipid peroxidation, increases the activity of the antioxidant system of enzymes, restores the structure and function of membranes disrupted in various pathologies, modulates membrane-bound enzymes (calcium-independent phosphodiesterase, adenylyl cyclase, acetylcholinediesterase), ion channels, receptor complexes , including benzodiazepine, GABA, acetylcholine; improves the transport of neurotransmitters, synaptic transmission and the interconnection of brain structures. Increases the content of the brain dopamine.

    The mechanism of action of Mexifin® is due to its ability to enhance the compensatory activation of aerobic glycolysis. It reduces the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia, increasing the content of ATP and creatine phosphate; contributes to the preservation of the structural and functional organization of biomembranes.

    Mefifin® improves cerebral metabolism and blood supply to the brain, corrects disturbances in the regulatory and microcirculatory systems, suppressing the constriction of arterioles and precapillaries; improves rheological properties of blood, reducing aggregation of platelets, stabilizing the membrane structures of blood cells (red blood cells and platelets), preventing hemolysis; improves the immune system. Mefifin® has an anti-atherogenic effect, causing a regression of atherosclerotic changes in the arteries, reducing the level of cholesterol and low-density lipoproteins, restoring lipid homeostasis.

    Mefifin® improves the working capacity and resistance of the organism to the effects of various extreme damaging factors in oxygen-dependent pathological conditions (shock, stress, hypoxia and ischemia, cerebral circulation,physical and mental overload), intoxication with alcohol and antipsychotic drugs (neuroleptics).

    Pharmacokinetics:With a single and course application of Mexifin®, the maximum concentration in the blood plasma is achieved after 0.45-0.5 hours. When administered at a dose of 400-500 mg CmOh in blood plasma - 3.5-4 μg / ml. When intramuscular injection of the drug is determined in the blood plasma for 4 hours. Pharmacokinetic profiles do not differ significantly in single or continuous administration. It is excreted from the body with urine mainly in the form of glucuronconjugates and in small amounts in unchanged form.
    Indications:

    - Acute disorders of cerebral circulation (as part of combined therapy);

    - encephalopathy;

    - vegetative-vascular dystonia;

    - light cognitive disorders of atherosclerotic origin;

    - anxiety disorders in neurotic and neurosis-like states;

    - relief of withdrawal syndrome with alcoholism with prevalence of neurosis-like and vegetative-vascular disorders;

    - acute intoxication with antipsychotic drugs.

    Contraindications:

    Acute violations of liver and kidney function, increased individual sensitivity to the drug.

    Children's age, pregnancy, breastfeeding - due to insufficient study of the effect of the drug in these categories of patients.

    Dosing and Administration:

    Mefinin® is administered intramuscularly or intravenously (either by jet or by drip). Doses are selected individually. The duration of treatment and the dosage regimen depends on the severity of the patient's condition and the effectiveness of the treatment. Begin treatment with a dose of 50-100 mg 1-3 times a day, gradually increasing the dose to obtain a therapeutic effect. The maximum daily dose should not exceed 800 mg.

    With an infusion method of administration, the drug should be diluted in a saline solution of sodium chloride.

    Streaming Mefinin® is administered slowly for 5-7 minutes; drip - at a rate of 60 drops per minute.

    Acute disorders of cerebral circulation: in the combination therapy intravenously drip 200-300 mg in the first 2-4 days, then intramuscularly at 100 mg 3 times a day. The duration of the course is 10-14 days.

    Dyscirculatory encephalopathy (decompensation phase): intravenously struino or drip on 100 mg 2-3 times a day for 14 days, then intramuscularly at 100 mg per day for the next 14 days.

    Prevention of discirculatory encephalopathy: intramuscularly at 100 mg twice a day for 10-14 days.

    Light cognitive impairment in elderly patients and with anxiety disorders: intramuscularly at 100-300 mg per day for 14-30 days.

    Alcohol abstinence syndrome: 100-200 mg intramuscularly 2-3 times a day or intravenously drip 1-2 times a day for 5-7 days.

    Acute intoxication with antipsychotics: intravenously, 50-300 mg per day for 7-14 days, depending on the severity of the condition.

    When neurotic disorders and vegetative-vascular dystonia the drug is administered intramuscularly at a dose of 50-400 mg per day for 14 days.

    Side effects:

    Possible occurrence of individual adverse reactions: nausea and dry mouth; drowsiness; allergic reactions are possible.

    Overdose:

    Overdose may develop drowsiness.

    Interaction:

    It potentiates the action of benzodiazepine anxiolytics, anticonvulsant and antiparkinsonian agents.

    The drug reduces the toxic effects of ethyl alcohol.

    Special instructions:

    Currently, a number of drugs with a similar active substance ethylmethylhydroxypyridine succinate, that should be taken into account when carrying out therapy for other diseases, in the treatment of which drugs with this substance can be used.

    Effect on the ability to drive transp. cf. and fur:At the beginning of the drug treatment, it is necessary to refrain from engaging in potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.
    Form release / dosage:

    Solution for intravenous and intramuscular injection, 50 mg / ml.

    Packaging:

    Ampoules 2 ml or 5 ml.

    5 or 10 ampoules are placed in a contour mesh package.

    According to 1, 2, 4, 5 or 10 contour cell packs together with instructions for medical use in a pack from cardboard.

    Storage conditions:

    In a dry, protected from light place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the expiration date indicated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-001967/07
    Date of registration:07.08.2007 / 17.09.2014
    Expiration Date:Unlimited
    The owner of the registration certificate:BRENDFARMA, LLC BRENDFARMA, LLC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp27.04.2018
    Illustrated instructions
      Instructions
      Up